Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Last week the American media giant agreed to buy a 39% stake in the satellite broadcaster from under-bidder 21st Century Fox
AVO is developing a proton beam system that blasts cancer called LIGHT. The initials stand for Linac Image Guided Hadron Technology. The company’s kit is cheaper and smaller than the current units, which are almost prohibitively expensive
Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours
Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug
The strategic marketing group has seen revenues, profits and margins advance
The miner acquired a 50% stake in the Alaskan asset back in July along with its purchase of Zazu Metals.
HC Wainwright reckons the stock is worth US$30, which compares with the current price of US$17..
Proactive's early take on the day's small-cap news ...